GlassScriptPhysician profile
Andrew Marple
NPI 1083093769
$3,870.67
in general payments reported to CMS, 2019-2025
43 companies · $1,602 in 2025
The $1,602 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $450 · 2023: $620 · 2024: $1,199 · 2025: $1,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,368 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,367.66 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $457.83 | 2022-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $431.04 | 2023-2025 | |
| Lilly USA, LLC | $329.22 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $318.88 | 2023-2025 | |
| Janssen Biotech, INC. | $209.17 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Genentech USA, INC. | $189.95 | 2022-2025 | Polivy |
| Medtronic, INC. | $160.50 | 2023 | Signia |
| Hologic Sales and Service, LLC | $147.21 | 2025 | Sentimag, Magtrace |
| Genzyme Corporation | $136.68 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $135.26 | 2024-2025 | Opdivo, Camzyos |
| Ethicon US, LLC | $120.02 | 2022 | |
| Merck Sharp & Dohme LLC | $116.92 | 2024-2025 | Keytruda |
| Pharmacosmos Therapeutics INC. | $114.79 | 2023-2025 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $93.65 | 2023-2025 | Enhertu, Lynparza |
| Incyte Corporation | $79.22 | 2024-2025 | Monjuvi, Zynyz |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $63.01 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $55.18 | 2024-2025 | Alymsys, Neulasta, Avastin |
| Daiichi Sankyo INC. | $51.35 | 2024-2025 | Enhertu, Injectafer |
| Caris Mpi, INC. | $48.56 | 2025 | Mi Cancer Seek |
| Myriad Genetic Laboratories, INC. | $46.54 | 2024 | Myrisk |
| Alnylam Pharmaceuticals INC. | $46.02 | 2024-2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.47 | 2023-2025 | Jardiance |
| Gilead Sciences, INC. | $40.76 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $38.61 | 2025 | Libtayo |
| Taiho Oncology, INC. | $34.37 | 2024-2025 | |
| Pharmaessentia USA Corporation | $31.20 | 2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $24.24 | 2025 | |
| Scpharmaceuticals INC. | $23.14 | 2025 | |
| Tersera Therapeutics LLC | $22.42 | 2025 | Quzyttir |
| Telix Pharmaceuticals | $21.90 | 2023 | Illuccix |
| Array Biopharma INC | $21.85 | 2024 | Mektovi, Braftovi, Tukysa |
| Geron Corporation | $21.53 | 2025 | Rytelo |
| Tempus Ai, INC | $21.51 | 2024 | |
| Deciphera Pharmaceuticals INC. | $20.46 | 2025 | Romvimza, Qinlock |
| Puma Biotechnology, INC. | $20.34 | 2025 | |
| Emd Serono, INC. | $20.21 | 2024 | |
| Astellas Pharma US INC | $18.32 | 2024 | Xtandi |
| Morphosys, US INC. | $18.28 | 2023 | Monjuvi |
| Stemline Therapeutics INC. | $16.82 | 2024 | Orserdu |
| Exelixis INC. | $16.49 | 2025 | Cabometyx |
| Spectrum Pharmaceuticals INC. | $15.99 | 2025 | Rolvedon |
| Cvrx, INC. | $15.01 | 2023 | Barostim Neo System |
| Eisai INC. | $14.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Marple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.